A Study of ADRX-0706 in Select Advanced Solid Tumors

PHASE1Active, not recruitingINTERVENTIONAL
Enrollment

144

Participants

Timeline

Start Date

September 26, 2023

Primary Completion Date

September 30, 2025

Study Completion Date

December 31, 2026

Conditions
Solid TumorsTriple Negative Breast Cancer (TNBC)Urothelial CancerCervical Cancer
Interventions
DRUG

ADRX-0706

Antibody drug conjugate targeting Nectin-4

Trial Locations (21)

33610

Moffitt Cancer Center, Tampa

33709

Comprehensive Hematology Oncology, St. Petersburg

37203

Sarah Cannon Cancer Network, Nashville

43026

The Ohio State University Wexner Medical Center, Hilliard

48201

Karmanos Cancer Institute, Detroit

48202

Henry Ford Cancer, Detroit

49546

START Midwest, Grand Rapids

73104

Stephenson Cancer Center, Oklahoma City

77030

University of Texas MD Anderson Cancer Center, Houston

78229

START San Antonio, San Antonio

84119

START Mountain Region, West Valley City

90033

USC Norris Comprehensive Cancer Center, Los Angeles

90404

UCLA, Los Angeles

Unknown

Beijing University Third Hospital, Beijing

Fujian Cancer Hospital, Fujian

Sun Yat-sen University Cancer Center, Guangzhou

Hunan Cancer hospital, Hunan

Shandong Cancer Hospital, Jinan

Shanghai East Hospital, Shanghai

Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan

Wuhan Union Hospital, Wuhan

Sponsors
All Listed Sponsors
lead

Adcentrx Therapeutics

INDUSTRY